Compare Stocks: RHHBY, LLY, JNJ, and MRK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$278.02 +1.0%	$260.90	$173.33 ▼ $281.07	$670.00B	0.24	8.14 million shs	2.70 million shs
LLY Eli Lilly and Company	$1,158.09 -0.2%	$1,192.23	$712.05 ▼ $1,292.65	$1.09T	0.5	3.07 million shs	1.07 million shs
MRK Merck & Co., Inc.	$152.07 +0.3%	$133.66	$77.58 ▼ $156.92	$375.18B	0.21	10.80 million shs	2.78 million shs
RHHBY Roche	$55.42 +3.0%	$54.14	$39.50 ▼ $60.85	$353.06B	0.48	2.36 million shs	1.19 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	+1.51%	+1.92%	+8.29%	+20.72%	+55.01%
LLY Eli Lilly and Company	+0.09%	-2.60%	+3.40%	+3.16%	+57.99%
MRK Merck & Co., Inc.	+1.41%	-0.89%	+18.89%	+26.29%	+77.92%
RHHBY Roche	+1.39%	-5.38%	-2.27%	+4.38%	+31.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$278.02 +1.0%	$260.90	$173.33 ▼ $281.07	$670.00B	0.24	8.14 million shs	2.70 million shs
LLY Eli Lilly and Company	$1,158.09 -0.2%	$1,192.23	$712.05 ▼ $1,292.65	$1.09T	0.5	3.07 million shs	1.07 million shs
MRK Merck & Co., Inc.	$152.07 +0.3%	$133.66	$77.58 ▼ $156.92	$375.18B	0.21	10.80 million shs	2.78 million shs
RHHBY Roche	$55.42 +3.0%	$54.14	$39.50 ▼ $60.85	$353.06B	0.48	2.36 million shs	1.19 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	+1.51%	+1.92%	+8.29%	+20.72%	+55.01%
LLY Eli Lilly and Company	+0.09%	-2.60%	+3.40%	+3.16%	+57.99%
MRK Merck & Co., Inc.	+1.41%	-0.89%	+18.89%	+26.29%	+77.92%
RHHBY Roche	+1.39%	-5.38%	-2.27%	+4.38%	+31.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.80	Moderate Buy	$272.83	-0.87% Downside
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,292.18	12.12% Upside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$147.60	-1.66% Downside
RHHBY Roche	2.45	Hold	$60.00	9.49% Upside

Current Analyst Ratings Breakdown

Latest RHHBY, LLY, JNJ, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$280.00 ➝ $320.00
9/1/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Buy
8/26/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/25/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/25/2026	MRK Merck & Co., Inc.	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$155.00 ➝ $180.00
8/25/2026	MRK Merck & Co., Inc.	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $170.00
8/24/2026	RHHBY Roche	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/21/2026	MRK Merck & Co., Inc.	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$140.00 ➝ $160.00
8/20/2026	MRK Merck & Co., Inc.	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$142.00 ➝ $170.00
8/20/2026	MRK Merck & Co., Inc.	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $175.00
8/20/2026	MRK Merck & Co., Inc.	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$142.00 ➝ $150.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$97.93B	6.77	$14.33 per share	19.21	$35.26 per share	7.81
LLY Eli Lilly and Company	$79.67B	13.62	$24.97 per share	46.15	$35.99 per share	32.02
MRK Merck & Co., Inc.	$65.01B	5.70	$11.44 per share	13.12	$17.02 per share	8.82
RHHBY Roche	$76.45B	4.57	$3.72 per share	14.74	$7.18 per share	7.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$8.63	31.88	21.50	2.59	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	38.59	25.13	1.44	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	119.77	15.54	6.52	4.77%	16.73%	6.13%	10/29/2026 (Estimated)
RHHBY Roche	$15.55B	N/A	N/A	16.61	3.32	N/A	N/A	N/A	N/A

Latest RHHBY, LLY, JNJ, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.36	1.95%	+5.25%	62.11%	64 Years
LLY Eli Lilly and Company	$6.92	0.60%	+15.18%	23.22%	11 Years
MRK Merck & Co., Inc.	$3.40	2.27%	+5.75%	272.00%	14 Years
RHHBY Roche	$0.97	1.77%	N/A	N/A	N/A

Latest RHHBY, LLY, JNJ, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.61%	9/15/2026	9/15/2026	10/7/2026
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	1.96%	8/25/2026	8/25/2026	9/8/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.44	1.09	0.81
LLY Eli Lilly and Company	1.41	1.35	1.00
MRK Merck & Co., Inc.	1.22	1.32	1.10
RHHBY Roche	0.72	1.38	1.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
RHHBY Roche	N/A

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.17%
RHHBY Roche	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.46 billion	Optionable
RHHBY Roche	103,249	6.37 billion	N/A	Not Optionable

RHHBY, LLY, JNJ, and MRK Headlines

Recent News About These Companies

Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 in Combination with CD20xCD3 T-Cell-Engaging Bispecific Antibodies

September 2 at 9:35 AM | finance.yahoo.com

Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion

September 1 at 6:32 PM | finance.yahoo.com

Astra, Daiichi granted EU nod for Enhertu in first-line breast cancer

September 1 at 1:32 PM | msn.com

Roche signs global licensing pact for Simcere's experimental blood cancer drug

September 1 at 7:03 AM | reuters.com

FY2026 EPS Estimates for Roche Boosted by Erste Group Bank

August 31 at 1:12 AM | marketbeat.com

North Star Asset Management Inc. Takes $1.35 Million Position in Roche Holding AG $RHHBY

August 29, 2026 | marketbeat.com

Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)

August 28, 2026 | uk.finance.yahoo.com

FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now

August 27, 2026 | zacks.com

Roche (OTCMKTS:RHHBY) Upgraded by Zacks Research to Hold Rating

August 26, 2026 | marketbeat.com

FDA clears Roche’s Alzheimer’s blood test for rule-in and rule-out assessment

August 24, 2026 | massdevice.com

Roche and Eli Lilly win FDA clearance for Alzheimer’s blood test

August 24, 2026 | msn.com

Roche Elecsys pTau217 receives FDA clearance for Alzheimer’s disease assessment

August 24, 2026 | msn.com

FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly

August 24, 2026 | wsj.com

Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance

August 24, 2026 | reuters.com

Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care

August 24, 2026 | finance.yahoo.com

Roche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of "Hold" from Analysts

August 24, 2026 | marketbeat.com

Roche stock holds firm after half-year sales reached CHF 30.4 billion

August 22, 2026 | ad-hoc-news.deA

Genentech Announces Manufacturing Expansion in Hillsboro, Oregon

August 20, 2026 | finance.yahoo.com

Roche’s US subsidiary Genentech announces manufacturing expansion in the United States

August 20, 2026 | finance.yahoo.com

Roche’s Genentech unit to build $750M fill-finish facility in Ohio

August 20, 2026 | seekingalpha.com

Puzo Michael J Makes New $1.23 Million Investment in Roche Holding AG $RHHBY

August 20, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RHHBY, LLY, JNJ, and MRK Company Descriptions

Johnson & Johnson NYSE:JNJ

$278.02 +2.81 (+1.02%)

As of 02:34 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$1,158.09 -1.99 (-0.17%)

As of 02:34 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$152.07 +0.43 (+0.28%)

As of 02:34 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Roche OTCMKTS:RHHBY

$55.42 +1.59 (+2.95%)

As of 02:29 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RHHBY, LLY, JNJ, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RHHBY, LLY, JNJ, and MRK Earnings

Compare Dividends

Latest RHHBY, LLY, JNJ, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RHHBY, LLY, JNJ, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RHHBY, LLY, JNJ, and MRK Company Descriptions

Johnson & Johnson NYSE:JNJ

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Roche OTCMKTS:RHHBY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools